Gyrolab xPlore™ immunoassay system

Discover how the Gyrolab® transforms immunoassay workflows by automating ELISA, cutting sample and reagent usage, and delivering results up to four times faster, boosting productivity and data quality in bioprocessing and bioanalysis.

In this white paper, Gyros Protein Technologies discusses the crucial role of immunoassay platforms in ensuring the timely release of safe and effective cell and gene therapeutics. Choosing the right platform involves considering various factors, including robustness, quick data generation from limited samples, support for rapid method development, and flexibility for novel assays. Automation and walk-away systems are essential for reducing manual labor and minimizing errors, allowing personnel to focus on more critical tasks. Additionally, ready validation and software that enables 21 CFR Part 11 compliance are necessary to meet regulatory guidelines.

In this white paper, Gyros Protein Technologies illustrates the contribution of automated flow-through microfluidic immunoassays using Gyrolab system in generating reliable data for applications in public health and the development of vaccines and antibody-based treatments.

The drive to generate preclinical and clinical data from smaller volumes of precious sample has led to considerable developments in sampling methods, In this white paper Gyros Protein Technologies describe the most common methods used for microsampling and their respective advantages and disadvantages, how microsampling is being used in preclinical and clinical studies as well as in diagnostics. Download the white paper below to find out a whole host of biopharmaceutical implications via microsampling.

Building on advances in microfluidics, next-generation immunoassays offer unparalleled capability in automation and miniaturization, generating robust and reproducible results for faster decision-making.

In this eBook, discover the advantages of automated, miniaturized immunoassays across the drug development pathway, from pre-clinical to bioprocessing. Learn about challenges and trends in immunoassay technology and how automated, miniaturized immunoassays can help you maximize productivity across a range of biopharmaceutical applications, including:

• Research and clinical development
• Insulin quantification
• Anti-drug antibody studies
• In-solution affinity determination
• Vaccine development and production
  

In this white paper, Gyros Protein Technologies demonstrates how high-quality reagents from Sino Biological can be used in a high-performance, one-hour microfluidic, nanoliterscale immunoassay using Gyrolab® platform for the qualitative detection of total antibodies generated against the receptor binding domain (RBD) of the spike protein of SARS-CoV-2 in human serum samples.

Download it below to explore details of the miniaturized, microfluidic SARS-CoV-2 antibody immunoassay development and learn more about the future directions for Gyrolab assay development to detect SARS-CoV-2 antibodies.

Advance gene therapy precision by reliably testing pre-existing AAV immunogenicity

Find out how Custom Assay Services from Gyros Protein Technologies accelerate biotherapeutic development

Watch exclusive interviews with industry experts on the key to vaccine development success, the role of biomaterials in creating drug models, and more

Explore the latest application eBooks with top tips on biopharmaceutical characterization and high-content screening

Johan Engström, Senior Scientist at Gyros Protein Technologies, discusses the challenges of measuring high-affinity interactions of ligands in cancer immunotherapy

Guest editorial: Technology to meet the challenge of efficiency in the regulated AAV vector space

EMD Serono senior scientist Carina Carter shares her experience with some of the latest immunoassay technology optimizing pharmacokinetics and immunogenicity assay development

Guest editorial: Technology to meet the needs of faster vaccine development